Lowe brings extensive experience serving as an
executive and board member for early, research-stage biotechnology
companies
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;
TSX.V:BTI), a biopharmaceutical company focused on overcoming
the limitations of therapeutic drug delivery across the blood-brain
barrier (BBB) and into the central nervous system for the treatment
of neurological diseases and disorders, today announced the
appointment of Christopher P. Lowe, M.B.A., as chief financial
officer and board advisor. Lowe will report to Mark Day, Ph.D.,
president and chief executive officer of biOasis and will be
responsible for the company’s corporate and financial
strategy, including transactions and fundraising.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171002005702/en/
Bioasis appoints Christopher P. Lowe,
M.B.A. as chief financial officer and advisor to the board of
directors. Lowe brings extensive experience serving as an executive
and board member for early, research-stage biotechnology companies.
(Photo: Business Wire)
“Chris is an impressively accomplished executive who brings
significant corporate and financial experience to biOasis,
including the strategic transactional, fundraising and M&A
expertise needed to advance the company,” said Dr. Day. “We are
fortunate to have him join us and I truly look forward to working
with Chris during this transformational time for biOasis.”
“I believe in the incredible potential of the biOasis
proprietary blood-brain barrier technology platform. I am eager to
work with Mark, the board of directors and the leadership team to
develop a meaningful path forward for biOasis,” said Lowe.
About Christopher P. Lowe, M.B.A.
Christopher P. Lowe, M.B.A., has over 15 years of senior
management experience as president, chief business officer and
chief financial officer (CFO) of various private and public life
sciences, medical technology and technology companies. Since
January 2014, Mr. Lowe has been a partner at FLG Partners, a
leading CFO services and board advisory firm in Silicon Valley,
where he also sits on FLG’s Management Committee. Prior to joining
FLG, Lowe served as a strategy, financial and management consultant
to several public and private companies, assisting them with
financings, market due diligence, Wall Street communications and
exits. Additionally, he has served as a member of the board of
directors of both public and private companies, and has chaired
their respective audit committees and compensation
committees. Lowe helps companies succeed by assisting them
with corporate and financial strategy, including early stage
financing, successive fundraising and initial public offerings
(IPO), public company advising and Wall Street communications,
licensing transactions, mergers & acquisitions (M&A),
restructurings and coaching at every level of the
C-Suite. Lowe excels at helping companies navigate the
challenges of accessing capital, M&A, licensing, restructurings
and exits.
During his career as a C-level executive, Lowe has successfully
raised over $500M in private and public financings, completed over
$1.0B in M&A transactions, negotiated over $300M in debt
instruments for companies, and has overseen three SOX-404
implementations. Lowe has been chief executive officer and
president of Inspyr Therapeutics, Inc., since Aug. 2, 2016 and also
serves as its CFO. Lowe has been chief accounting officer of
Diadexus, Inc., since Dec. 22, 2014 and served as its interim CFO.
He served as an interim CEO of Hansen Medical, Inc., from
February 2014 to May 23, 2014. He served as an interim CFO and
principal accounting officer of Hansen Medical, Inc., from June 10,
2014 to July 27, 2016.
As vice president and chief accounting officer, he drove a
parallel M&A and IPO path resulting in the sale of Peninsula
Pharmaceuticals to Johnson & Johnson for over $300M in 2005,
including the design of a tax efficient spinout for assets which
were undervalued by Johnson & Johnson. As CFO of Asthmatx,
a medical technology company, he actively drove strategic supply
negotiations and led the parallel M&A and IPO process resulting
in a $50M strategic investment from Olympus Medical and ultimately
the sale of the company to Boston Scientific in a deal valued at
approximately $400M. As its CFO, he also took Anthera
Pharmaceuticals, a pharmaceutical development company, public in
2010 during the height of the financial crisis, raising over $300M
in both the private and public markets during his tenure.
Lowe earned his bachelor of science degree in business
administration from California Polytechnic State University, San
Luis Obispo, and a master’s of business degree from St. Mary’s
University. Lowe currently sits on the board of directors of
the following public and private companies: EpiBiome (private;
2016-present); Hansen Medical (NASDAQ: HNSN; 2006-present); Pacific
Pharmaceuticals (private; 2010-present); and Career Closet
(Non-Profit; 2009-present).
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company focused
on overcoming the limitations of therapeutic drug delivery across
the blood-brain barrier (BBB). The delivery of therapeutics across
the BBB represents the single greatest challenge in treating
neurological disorders. The company is developing and
commercializing the xB3 platform, biOasis’ proprietary
blood-brain barrier delivery technology, to address unmet medical
needs in the treatment of central nervous system diseases and
disorders. The company maintains headquarters in Vancouver, Canada
with offices in Connecticut, United States. biOasis trades on the
OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange
under the symbol “BTI.” For more information about the company
please visit www.bioasis.ca.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”,
“anticipate”, “intend”, “expect” and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments express or implied by such forward-looking statements
or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in
our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching
our products may be greater than anticipated; we have no experience
in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
On Behalf of the Board of DirectorsMark Day, Ph.D., President
& Chief Executive OfficerbiOasis Technologies, Inc.
“Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release”
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171002005702/en/
biOasis Technologies Inc.Catherine London,
917-763-2709Catherine@bioasis.usorGraeme Dick,
403-561-8989investors@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
